Cargando…
Crizotinib treatment for refractory pediatric acute myeloid leukemia with RAN-binding protein 2-anaplastic lymphoma kinase fusion gene
Autores principales: | Hayashi, A, Tanoshima, R, Tsujimoto, S-I, Yanagimachi, M, Takeuchi, M, Sasaki, K, Ikeda, J, Kajiwara, R, Ito, S, Takahashi, H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5022176/ https://www.ncbi.nlm.nih.gov/pubmed/27494825 http://dx.doi.org/10.1038/bcj.2016.52 |
Ejemplares similares
-
Clinical Courses of Two Pediatric Patients with Acute Megakaryoblastic Leukemia Harboring the CBFA2T3-GLIS2 Fusion Gene
por: Ishibashi, Mayu, et al.
Publicado: (2016) -
Association of isochromosome (7)(q10) in Shwachman–Diamond syndrome with the severity of cytopenia
por: Shimosato, Yuko, et al.
Publicado: (2017) -
Combination therapy with crizotinib and vinblastine for relapsed or refractory pediatric ALK-positive anaplastic large cell lymphoma
por: Knörr, Fabian, et al.
Publicado: (2022) -
Crizotinib in Combination with Everolimus Synergistically Inhibits Proliferation of Anaplastic Lymphoma Kinase‒Positive Anaplastic Large Cell Lymphoma
por: Xu, Wendan, et al.
Publicado: (2018) -
Crizotinib in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma in the setting of renal insufficiency: a case report
por: Kothari, Shalin, et al.
Publicado: (2016)